Covista (formerly Adtalem) posts 9.3% revenue growth to $1.95B; net income +6.1% to $251.6M

Filed August 6, 2026 · Period ending June 30, 2026 · Compared to 10-K Aug 7, 2025 · ~2 min read

Key Changes

• high

  Revenue grew 9.3% to $1.95B in FY26, decelerating from 12.9% in FY25, with net income up 6.1% to $251.6M and diluted EPS rising 13.9% to $7.04 aided by $239.9M in share repurchases.

  MD&A: Consolidated Results verify on EDGAR →
• high

  Chamberlain revenue growth slowed sharply to 3.4% (from 14.6%) and adjusted operating income fell 6.3% as enrollment growth decelerated to 1.1% and costs (labor, marketing, growth investments) outpaced revenue gains.

  MD&A: Chamberlain Segment verify on EDGAR →
• high

  Medical and Veterinary revenue growth accelerated to 8.1% (from 3.7%) and adjusted operating income rose 15.5% as enrollment momentum improved to 4.5% average growth, reversing the prior year's near-flat performance.

  MD&A: Medical and Veterinary Segment verify on EDGAR →